Breast cancer: metoprolol prophylaxis for anthracycline cardiotoxicity

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Anthracycline treatment for breast cancer has well-established cardiotoxicity.
  • The beta-blocker metoprolol, but not candesartan, when given with anthracycline, reduces the elevation in circulating cardiotoxic biomarker troponin but has no effect, as yet, on developing ventricular ...